Lecanemab, Clinical Trials, and the Importance of Clinical Meaningfulness
Dementia Matters14 Kesä 2023

Lecanemab, Clinical Trials, and the Importance of Clinical Meaningfulness

On June 9, 2023, the Food and Drug Administration’s (FDA) advisory committee unanimously voted to approve lecanemab, moving the treatment one step closer to full FDA approval. In the lead up to the FDA’s official announcement expected in early July, Dr. Paul Aisen joins the podcast to discuss Alzheimer’s disease clinical trials. Aisen, the founding director of the Alzheimer’s Therapeutic Research Institute (ATRI) and a leading figure in Alzheimer’s disease research for over three decades, talks about the Phase 3 clinical trials for lecanemab and gantenerumab and shares highlights from the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference.

Guest: Paul Aisen, MD, professor of neurology, Keck School of Medicine, University of Southern California, Director, Alzheimer’s Therapeutic Research Institute

Show Notes

Find out more about Dr. Aisen on Keck School of Medicine’s website.

Follow the Alzheimer’s Therapeutic Research Institute on Facebook andTwitter.

Listen to the episode with Dr. Roderick Corriveau, “Mixed Dementia, Explained” on our website, Spotify, Apple Podcasts, Podbean, and all major podcast platforms.

Connect with us

Find transcripts and more at our website.

Email Dementia Matters: dementiamatters@medicine.wisc.edu

Follow us on Facebook and Twitter.

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(246)

Examining Environmental Factors' Effects on Cognition

Examining Environmental Factors' Effects on Cognition

New research is looking at the effects of environmental factors on the brain as we age. Dr. Kathryn Conlon joins the podcast to discuss how factors like air pollution and lead exposure can affect cogn...

22 Syys 42min

Blood Tests and Brain Scans and Biomarkers, Oh My! How Biomarkers are Changing Alzheimer’s Disease Clinical Trials

Blood Tests and Brain Scans and Biomarkers, Oh My! How Biomarkers are Changing Alzheimer’s Disease Clinical Trials

In recent years, the U.S. Food and Drug Administration (FDA) has approved new biomarker tools for Alzheimer’s disease, including blood tests and tracers for brain scans. How are these tools used in re...

8 Syys 45min

New Alzheimer’s Association Special Report Breaks Down How Americans Understand and Support their Brain Health

New Alzheimer’s Association Special Report Breaks Down How Americans Understand and Support their Brain Health

In recent years, public interest in brain health has increased. So how are Americans understanding brain health information and incorporating it into their own lives? This year, the Alzheimer’s Associ...

25 Elo 37min

Reflecting on 25 Years of the Wisconsin Registry for Alzheimer’s Prevention

Reflecting on 25 Years of the Wisconsin Registry for Alzheimer’s Prevention

Twenty-five years ago, a single participant enrolled in what would become the Wisconsin Registry for Alzheimer's Prevention (WRAP), now one of the largest and longest-running studies of Alzheimer's ri...

12 Elo 35min

How Dementia Caregiving Affects the Spousal Caregiver

How Dementia Caregiving Affects the Spousal Caregiver

Caring for those with dementia represents a major public health challenge, with caregivers, especially spouses, providing long-term, largely unpaid care. With caregiving stress linked to a decline in ...

28 Heinä 39min

Managing the Medicine Cabinet: How Prescriptions Impact Cognition and Brain Health as We Age

Managing the Medicine Cabinet: How Prescriptions Impact Cognition and Brain Health as We Age

Prescription medications, over-the-counter drugs and supplements are incredibly common among older adults, yet many of these routine treatments can unexpectedly impact cognitive function and brain hea...

14 Heinä 35min

Taking a Deep Dive into Subjective Cognitive Decline

Taking a Deep Dive into Subjective Cognitive Decline

Dr. Jessen returns to the podcast to take a deeper dive into subjective cognitive decline (SCD). Aiming to cover everything relating to SCD, Dr. Jessen shares insights in prognosis, risk factors and h...

7 Heinä 17min

Defining Subjective Cognitive Decline

Defining Subjective Cognitive Decline

Subjective cognitive decline (SCD) can be one of the earliest noticeable signs of Alzheimer's disease, yet SCD is not yet fully understood. To help us understand more, Dr. Frank Jessen, an expert in t...

30 Kesä 30min

Suosittua kategoriassa Tiede

rss-mita-tulisi-tietaa
rss-poliisin-mieli
rss-hereilla
tiedekulma-podcast
utelias-mieli
rss-luontopodi-samuel-glassar-tutkii-luonnon-ihmeita
rss-tiedetta-vai-tarinaa
docemilia
rss-duodecim-lehti
rss-bios-podcast
university-of-eastern-finland
hippokrateen-vastaanotolla
rss-radplus
radio-antro
rss-ranskaa-raakana